IL17A and psoriasis: Following the relative success of TNF and IL-6R blockers in clinic, it is likely that the list of licensed therapies will soon include other blocking antibodies, such as those specific for IL-17 (secukinumab and ixekizumab) [12,13], IL-17R (brodalumab) [14] or the p40 subunit common to both IL-12 and IL-23 (ustekinumab) [15,16], that are currently approved for treatment of other IL-17-dependent autoimmune diseases such as psoriasis.